Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis

Human mesenchymal stem cells (hMSCs) are being considered for clinical trials of multiple sclerosis (MS). We examined the effects of adult bone marrow‐derived hMSCs on responses of primary human Th1, Th17, and Th1/17 double‐expressing T‐cell subsets, all implicated in MS. As expected, soluble products from hMSCs inhibited Th1 responses; however, Th17 responses were increased. Secretion of interleukin (IL)‐10, considered anti‐inflammatory, was decreased. Pretreating hMSCs with the proinflammatory cytokine IL‐1β accentuated these effects, and caused decreases in the Th1/17 subset. These findings underscore the importance of further preclinical work and immune‐monitoring to define hMSC effects on disease‐relevant immune responses under variable conditions. ANN NEUROL 2010

[1]  Keith A. Johnson,et al.  Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy , 2010, Annals of neurology.

[2]  H. Atkins,et al.  The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group , 2010, Multiple sclerosis.

[3]  Jiuhong Kang,et al.  MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis , 2009, Nature Immunology.

[4]  Zhenping Chen,et al.  Fetal BM‐derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells , 2009, European journal of immunology.

[5]  P. Duquette,et al.  Preferential recruitment of interferon‐γ–expressing TH17 cells in multiple sclerosis , 2009, Annals of neurology.

[6]  S. Miller,et al.  Human bone marrow‐derived mesenchymal stem cells induce Th2‐polarized immune response and promote endogenous repair in animal models of multiple sclerosis , 2009, Glia.

[7]  K. Schäkel,et al.  Mesenchymal stem cells efficiently inhibit the proinflammatory properties of 6-sulfo LacNAc dendritic cells , 2009, Haematologica.

[8]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[9]  A. Uccelli,et al.  Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks , 2009, Bone Marrow Transplantation.

[10]  D. Wraith,et al.  Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration , 2008, Neuroscience Letters.

[11]  D. Karussis,et al.  The potential use of stem cells in multiple sclerosis: An overview of the preclinical experience , 2008, Clinical Neurology and Neurosurgery.

[12]  K. Bendtzen,et al.  T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis , 2008, Immunology.

[13]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[14]  C. Crescioli,et al.  Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment , 2008, Journal of Neuroimmunology.

[15]  J. Trojanowski,et al.  Concomitant TAR-DNA-Binding Protein 43 Pathology Is Present in Alzheimer Disease and Corticobasal Degeneration but Not in Other Tauopathies , 2008, Journal of neuropathology and experimental neurology.

[16]  R. Zhao,et al.  Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. , 2008, Cell Stem Cell.

[17]  D. Arnold,et al.  Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. , 2007, Archives of neurology.

[18]  Joylee Wu,et al.  The National Alzheimer's Coordinating Center (NACC) Database: The Uniform Data Set , 2007, Alzheimer disease and associated disorders.

[19]  A. Uccelli,et al.  Mesenchymal stem cells: a new strategy for immunosuppression? , 2007, Trends in immunology.

[20]  Sergio Romagnani,et al.  Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .

[21]  Marvin Bergsneider,et al.  Development of Guidelines for Idiopathic Normal-pressure Hydrocephalus: Introduction , 2005, Neurosurgery.

[22]  G. Mancardi,et al.  Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. , 2005, Blood.

[23]  O. Koç,et al.  Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. , 2005, Experimental hematology.

[24]  V. Goldberg,et al.  FGF‐2 enhances the mitotic and chondrogenic potentials of human adult bone marrow‐derived mesenchymal stem cells , 2005, Journal of cellular physiology.

[25]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[26]  M. Poca,et al.  Is the placement of shunts in patients with idiopathic normal-pressure hydrocephalus worth the risk? Results of a study based on continuous monitoring of intracranial pressure. , 2004, Journal of neurosurgery.

[27]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[28]  J. Trojanowski,et al.  Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases , 2002, Annals of neurology.

[29]  R. Gur,et al.  Neuropsychological functioning in elderly patients with schizophrenia and Alzheimer's disease , 2002, Schizophrenia Research.

[30]  A. Caplan,et al.  Dilution of human mesenchymal stem cells with dermal fibroblasts and the effects on in vitro and in vivo osteochondrogenesis , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[31]  B. Stegmayr,et al.  Three-year survival and functional outcome of patients with idiopathic adult hydrocephalus syndrome , 2000, Neurology.

[32]  A. Kluger,et al.  Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response , 2000, Journal of neurology, neurosurgery, and psychiatry.

[33]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[34]  F. Schmitt,et al.  Alzheimer neuropathologic alterations in aged cognitively normal subjects. , 1999, Journal of neuropathology and experimental neurology.

[35]  H. Braak,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[36]  W. Halliday,et al.  Neuropathological Changes in Chronic Adult Hydrocephalus: Cortical Biopsies and Autopsy Findings , 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[37]  M. Goedert,et al.  Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404 , 1994, Journal of neuroscience research.

[38]  O Ouchterlony,et al.  A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. , 1983, Journal of immunological methods.

[39]  L. Steinman.  Mixed results with modulation of TH-17 cells in human autoimmune diseases , 2010, Nature Immunology.

[40]  Sergio Romagnani,et al.  Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. , 2006, Stem cells.

[41]  A. Marmarou,et al.  Three-year outcome of shunted idiopathic NPH patients. , 2005, Acta neurochirurgica. Supplement.

[42]  R. Doms,et al.  Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. , 2003, The Journal of biological chemistry.

[43]  G. Waldemar,et al.  Shunting Effects in Patients with Idiopathic Normal Pressure Hydrocephalus; Correlation with Cerebral and Leptomeningeal Biopsy Findings , 1999, Acta Neurochirurgica.

[44]  K. M. Gill,et al.  Clinical Gait Assessment in the Neurologically Impaired , 1984 .